Clinical trials: Lymphoma, Non-Hodgkin
Cancer, Neoplasms
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma
This is an open-label, multicenter, 2-part study to determine the recommended Phase 2 dose (RP2D) for GSK2816126 given twice weekly by intravenous (IV) infusion.
- Trial name
- NCT02082977
- Testing
- GSK2816126
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 41 people
- Sponsor
- GlaxoSmithKline
B-Cell Non-Hodgkin Lymphoma (NHL)
Non-Interventional Study of Ranicabtagene Autoleucel Injection for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Establishing real-world data of patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) treated with Ranicabtagene Autoleucel Injection to evaluate its efficacy and safety.
- Trial name
- NCT07888530
- Testing
- Ranicabtagene Autoleucel Injection
- Volunteers
- 200 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Diffuse Large B Cell Lymphoma
Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL
To compare the efficacy outcomes of the L-MIND cohort with the effectiveness in a matched patient population treated with systemic NCCN/ESMO guideline listed regimens administered in routine clinical care.
- Trial name
- RE-MIND2 (NCT04697160)
- Where
- 165 sites in United States, Australia and 10 more
- Volunteers
- 3,573 people
- Sponsor
- MorphoSys AG
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
- Trial name
- VITALIZE (NCT04920617)
- Testing
- DPX-Survivac, Pembrolizumab, CPA
- Where
- 50 sites in United States, Australia and 8 more
- Volunteers
- 102 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
B-Cell Non-Hodgkin Lymphoma (B-NHL)
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding to…
- Trial name
- OLYMPIA-4 (NCT06230224)
- Testing
- Odronextamab, Ifosfamide, Carboplatin
- Where
- 81 sites in Argentina, Australia and 12 more
- Volunteers
- 216 people
- Sponsor
- Regeneron Pharmaceuticals
Lymphoma, Lymphoma, B-Cell
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma
This is a Phase 1, multi-center, open-label study of TRPH-222 monotherapy in subjects with relapsed and/or refractory B-cell NHL. The study will be conducted in two Stages: Dose-Escalation, Dose-Expansion.
- Conditions
- Lymphoma, Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell
- Trial name
- NCT03682796
- Testing
- TRPH-222
- Where
- 7 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- Triphase Research and Development III Corp.
Hematologic Malignancies
Repeat Dose Safety Study for Compound to Treat Hematologic Cancer
The purpose of this study is to characterize the safety and tolerability of repeat doses of compound GSK2110183 in subjects with hematologic cancer.
- Trial name
- NCT00881946
- Testing
- GSK21110183
- Where
- 4 sites in Australia, Canada and 1 more
- Volunteers
- 73 people
- Sponsor
- Accenture
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma
To assess the blood levels of hypericin and any electrocardiogram (ECG) changes during 8 weeks of HyBryte (topical hypericin ointment) photodynamic therapy.
- Trial name
- NCT05380635
- Testing
- Hypericin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Soligenix
Lymphoma
Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill cancer…
- Trial name
- NCT00030589
- Testing
- bexarotene, methoxsalen, UV light therapy
- Where
- 19 sites in United States
- Sponsor
- Millennix
Lymphoma, Large-Cell, Diffuse
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
This study is being conducted to compare the efficacy and safety of ofatumumab in addition to salvage chemotherapy versus rituximab in addition to salvage chemotherapy in CD20 positive DLBCL subjects relapsing, or with persistent…
- Trial name
- ORCHARRD (NCT01014208)
- Testing
- OFATUMUMAB + DHAP, RITUXIMAB + DHAP
- Where
- 173 sites in United States, Argentina and 24 more
- Volunteers
- 447 people
- Sponsor
- GlaxoSmithKline
Neoplasms, Hodgkin's Disease
Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies
Tapestry Pharmaceuticals, Inc. has developed a novel taxane analog, TPI 287. TPI 287 is synthetically manufactured from naturally occurring taxanes extracted from yew starting material.
- Conditions
- Neoplasms, Hodgkin's Disease, Non-Hodgkin's Lymphoma
- Trial name
- NCT00256191
- Testing
- TPI 287 Injection
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Cortice Biosciences, Inc.
Mantle Cell Lymphoma
VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
The purpose of this study is to find out whether treatment with VELCADE will increase the time it takes for lymphoma to get worse.
- Trial name
- NCT00063713
- Testing
- VELCADE TM (bortezomib) for Injection
- Where
- 35 sites in United States
- Volunteers
- 152 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Neoplasms by Site, Lymphoma, Non-hodgkin
Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients
To determine the highest dose of study drug that can be taken without causing serious side effects in patients with advanced cancer.
- Conditions
- Neoplasms by Site, Lymphoma, Non-hodgkin, Hodgkin Disease, Multiple Myeloma
- Trial name
- NCT00562224
- Testing
- PCI-24781
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Pharmacyclics LLC.
Asthma
Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years
A double blind, double dummy, randomised, multicentre, two arm parallel group study to assess the efficacy and safety of FLUTIFORM® pMDI (2 puffs bid) vs Seretide® pMDI (2 puffs bid) in subjects aged ≥12 years with moderate to…
- Trial name
- NCT03387241
- Testing
- Fluticasone/ Formoterol, fluticasone/ salmeterol
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Chronic Myeloproliferative Disorders, Infection
Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer
RATIONALE: Antifungal therapy with liposomal nystatin may reduce fever and neutropenia in patients undergoing treatment for hematologic cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Infection, Leukemia, Lymphoma
- Trial name
- NCT00002742
- Testing
- amphotericin B deoxycholate, nystatin
- Where
- 59 sites in United States
- Sponsor
- Aronex Pharmaceuticals
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia
The purpose of this study is to find answers to the following questions: What is the largest dose of AQ4N that can be given safely one time every three weeks for 24 weeks? What are the side effects of AQ4N when given according to…
- Conditions
- Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
- Trial name
- NCT00109356
- Testing
- AQ4N (Chemotherapy)
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Novacea
Non-Hodgkin Lymphoma
Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients
The purpose of the study was to assess the efficacy and safety of tisagenlecleucel in pediatric, adolescent and young adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) including Burkitt Lymphoma and…
- Trial name
- BIANCA (NCT03610724)
- Testing
- Tisagenlecleucel, lymphodepleting chemotherapy, Bridging Therapy
- Where
- 26 sites in United States, Australia and 12 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Non-Hodgkin Lymphoma
Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects with Refractory Non-Hodgkin Lymphoma (NHL)
- Trial name
- NHL (NCT02519270)
- Testing
- IGN002
- Where
- 2 sites in United States
- Volunteers
- 62 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Mantle Cell Lymphoma, B Cell Lymphoma
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL).
- Trial name
- NCT06742996
- Testing
- Sonrotoclax, Zanubrutinib
- Where
- 145 sites in United States, Argentina and 15 more
- Volunteers
- 300 people
- Sponsor
- BeOne Medicines
Lymphoma
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00053105
- Testing
- cisplatin, cytarabine, methylprednisolone
- Where
- 7 sites in United States
- Sponsor
- Theradex
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.